/
Other
Effectiveness
69
Pipeline Programs↗
90
Active Trials↗
89
Companies Involved↗
Effectiveness is a moderately active landscape with 69 programs across 89 companies. The most active players are Insud Pharma, Novartis, Merck & Co.. 23 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical34
Phase 210
Phase 323
Approved
No programs
Analysis
Modality Breakdown
85%
Small molecule
57 of 67 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 67 classified programs, each share of the total. Modality classified for 100% of 69 pipeline programs.
Analysis
Trial Status
866
clinical trials
Completed568 · 66%
Unknown status116 · 13%
Terminated58 · 7%
Recruiting47 · 5%
Withdrawn27 · 3%
Not yet recruiting24 · 3%
Other26 · 3%
Clinical Trials
Trial Activity
866 trials
Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus
Recruiting·IInstituto de Investigación Hospital Universitario La Paz·Phase 4·NCT06701825·114 enrolled
Observational RegIstry of Effectiveness and Safety of teNecTeplase in reAl worLd Settings in China
Recruiting·—·N/A·NCT07271342·10,000 enrolled
The Evaluation of the Effectiveness and Safety of Nalbuphine Hydrochloride Injection for Analgesia in ICU Patients: A Multicenter, Randomized, Single-blinded, Parallel, Two-step Trial
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2/3·NCT06785571·204 enrolled
Page 1 of 58
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)